News & Press

‍

Subscribe to get the latest clinical and R&D news

Thanks! You're subscribed.
Oops! Something went wrong while submitting the form.
  • December 2023
    |
    Press Release
    Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer TreatmentGradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
  • November 2023
    |
    News Article
    Texas backs Carrollton firm working on ovarian cancer drug with $10 million grantTexas backs Carrollton firm working on ovarian cancer drug with $10 million grant
  • November 2023
    |
    Press Release
    Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of TexasGradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
  • October 2023
    |
    Press Release
    Gradalis hosted KOL Discussion: Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian CancerGradalis hosted KOL Discussion: Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer
  • October 2023
    |
    Press Release
    Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum Sensitive Recurrent Ovarian Cancer on October 25, 2023Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum Sensitive Recurrent Ovarian Cancer on October 25, 2023
  • September 2023
    |
    Press Release
    Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews PublicationGradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
  • June 2023
    |
    Press Release
    Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil PlatformGradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform
  • March 2023
    |
    Press Release
    Gradalis to Participate in the Cantor Fitzgerald Future of Oncology SymposiumGradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
  • March 2023
    |
    Press Release
    Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's SarcomaGradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's Sarcoma
  • February 2023
    |
    Press Release
    Gradalis to Present at the 2023 BIO CEO & Investor ConferenceGradalis to Present at the 2023 BIO CEO & Investor Conference
  • December 2022
    |
    Press Release
    Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.
  • December 2022
    |
    Press Release
    Gradalis Appoints Eric Hall as Chief Financial OfficerGradalis Appoints Eric Hall as Chief Financial Officer
  • October 2022
    |
    Press Release
    Gradalis to Present at the 2022 Cell & Gene Meeting on the MesaGradalis to Present at the 2022 Cell & Gene Meeting on the Mesa
  • October 2022
    |
    Press Release
    Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint InhibitorsGradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors
  • September 2022
    |
    Press Release
    Gradalis KOL Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®Gradalis KOL Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®
  • September 2022
    |
    Press Release
    Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company's Immuno-Oncology Treatment, VigilGradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company's Immuno-Oncology Treatment, Vigil
  • September 2022
    |
    News Article
    Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer PatientsGradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients
  • August 2022
    |
    Press Release
    Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®
  • June 2022
    |
    Press Release
    Gradalis Appoints Steven Engle as Chief Executive OfficerGradalis Appoints Steven Engle as Chief Executive Officer
  • February 2022
    |
    Press Release
    Gradalis and University of Michigan collaboration to utilize a patient's cancer cells to create personalized therapeutics to treat cancerGradalis and University of Michigan collaboration to utilize a patient's cancer cells to create personalized therapeutics to treat cancer
  • March 2021
    |
    Press Release
    Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancerPhase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
  • January 2021
    |
    Press Release
    Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet OncologyGradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology
  • December 2020
    |
    News Article
    Dr. Rod Rocconi on Med School Watercooler: Significant Results for Ovarian Cancer PatientsDr. Rod Rocconi on Med School Watercooler: Significant Results for Ovarian Cancer Patients
  • December 2020
    |
    News Article
    Lancet Oncology: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trialLancet Oncology: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
  • June 2020
    |
    News Article
    Gradalis at ASCO Virtual Scientific Forum - Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancerGradalis at ASCO Virtual Scientific Forum - Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancer
  • April 2020
    |
    News Article
    Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian CancerFrontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer
  • June 2019
    |
    News Article
    Cancer Vaccine Developed In North Texas Could Be 'As Simple As A Flu Shot'Cancer Vaccine Developed In North Texas Could Be 'As Simple As A Flu Shot'
  • March 2019
    |
    Press Release
    Gradalis Announces Medical Leadership Team PromotionGradalis Announces Medical Leadership Team Promotion
  • November 2018
    |
    Press Release
    Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology GroupGradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group
  • October 2018
    |
    News Article
    Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcomaGradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcoma
  • August 2018
    |
    Press Release
    Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcomaGradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma
    Load more

    See how we can help

    Contact us

    About

    Product

    Get Help

    Gradalis, Inc.
    2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006
    (214) 442-8100 
phone     (214) 442-8101 fax
    info@gradalisinc.com
    Cookie Policy | Terms & Conditions | © Copyright 2022 Gradalis, Inc.